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Objective: Prosthetic arteriovenous fistulas for hemodialysis vascular access have a high incidence rate of thrombotic
occlusions that result in graft failure. This randomized multicenter study was performed to assess the patency rates and
the effect of 4-mm to 7-mm grafts on the development of stenoses.
Methods: A total of 109 patients who needed vascular access for hemodialysis were randomized to receive either 6-mm (n
57) or 4-mm to 7-mm prosthetic brachial-antecubital forearm loop accesses (polytetrafluoroethylene). Duplex scanning,
with measurement of blood flow and peak systolic velocity and detection of stenoses (>50%), was performed at 1, 6, and
12 months after surgery. Clinical data were obtained in a prospective manner and primary, assisted primary, and
secondary patency rates were calculated with the Kaplan-Meier life-table analysis. Statistical analysis was performed with
the independent samples t test and 2 test.
Results: At 1 year, patency rates were similar for both 4-mm to 7-mm and 6-mm prostheses (primary, 46% versus 43%;
assisted primary, 62% versus 58%; secondary, 87% versus 91%). The incidence rate of thrombotic occlusion was
comparable for both groups (0.74/patient-year versus 0.88/patient-year; P > .05). Mean graft flow at 1, 6, and 12
months was 1416 versus 1415 mL/min, 1345 versus 1319 mL/min, and 1595 versus 1265 mL/min (P > .05) for 4-mm
to 7-mm and 6-mm grafts, respectively. Also, no differences in peak systolic velocities in any part of the grafts were
observed. The percentage of stenoses detected was equal in both groups at 1 year after surgery (27% versus 20%; P > .05).
Conclusion: A 4-mm to 7-mm tapered prosthetic brachial-antecubital forearm loop access did not reduce the incidence
rates of stenoses and thrombotic occlusions compared with a 6-mm prosthetic conduit. Moreover, no differences in
patency rates were observed. Therefore, we believe that the 4-mm to 7-mm graft should not be used routinely for
hemodialysis vascular access. (J Vasc Surg 2003;37:143-8.)
Hemodialysis treatment requires creation and mainte-
nance of vascular access. The autogenous radial-cephalic
direct wrist access remains the angioaccess of choice.1 Nev-
ertheless, polytetrafluoroethylene grafts are increasingly
necessary because comorbid factors, such as age, cardiovas-
cular disease, and diabetes, have increased in the renal
failure population.2 Prosthetic arteriovenous fistulas have a
high incidence rate of thrombotic occlusions, 0.8 to 1.25
per patient-year (py),3-5 as a result of deterioration of graft
flow from intimal hyperplastic lesions.
Various studies have reported intimal hyperplasia at the
venous anastomosis and the venous outflow tract of the
graft to be the major cause of arteriovenous fistula graft
stenosis.6-8 Although many theories have been suggested
and the exact mechanism of intimal hyperplasia remains
tentative,9-16 the fluid dynamics within a vascular graft are
thought to have great influence on the initiation and devel-
opment of intimal hyperplasia.
For example, high shear stress is known to inhibit
vascular smooth muscle cell proliferation,17 yet high shear
stress may also cause damage to the endothelium and thus
inhibit the antiproliferative effect on smooth muscle
cells.7,18 Low shear stress, on the other hand, triggers
endothelial cells to release mitogenic factors and hence
might initiate intimal hyperplasia.9,15,19,20 Other factors,
such as graft-vein anastomotic compliance and anastomotic
angle geometry, have also been shown to be of importance
in determination of graft patency and local hemodynam-
ics.15,21
Different geometric configurations have been intro-
duced to influence fluid hemodynamics and ultimately
reduce shear stress–induced intimal hyperplasia.19,22-29
Graft tapering is one such configuration of which 4-mm to
7-mm and 6-mm to 8-mm prosthetic grafts have been used
in experimental research and clinical trials.19,25,27-32 Al-
though Fillinger et al27 showed less intimal hyperplasia at
the venous anastomosis of 4-mm to 7-mm tapered prosthe-
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ses in arteriovenous fistulas in mongrel dogs, the results of
these studies have been contradictory. Therefore, we con-
ducted a prospective randomized controlled multicenter
clinical trial in which we compared a 4-mm to 7-mm
tapered prosthetic brachial-antecubital forearm loop access
with a standard 6-mm prosthetic brachial-antecubital fore-
arm loop access. We hypothesized that, through its modi-
fied geometric configuration, the tapered graft would per-
form better hemodynamically, resulting in less stenotic
lesions and improved patency rates.
PATIENTS AND METHODS
Patients. The multicenter study, conducted between
August 1997 and December 2001, was approved by the
joint Medical Ethical Committee of the Maastricht Univer-
sity and the University Hospital Maastricht and the Medical
Ethical Committee of the two peripheral hospitals con-
cerned. Patients who were considered for secondary vascu-
lar access surgery or who had unsuitable vessels for primary
access were included after written informed consent was
given, and all entered the study only once. Computerized
randomization was used for randomizing for a 4-mm to
7-mm tapered or a 6-mm polytetrafluoroethylene prosthe-
sis. Patient characteristics and the use of drugs were regis-
tered.
Surgical procedure. All procedures were performed
with regional, local infiltration, or general anesthesia. Dur-
ing each procedure, prophylactic antibiotic therapy (Aug-
mentin, amoxicillin/clavulanate potassium, 1200 mg,
SmithKline Beecham Pharma, London, United Kingdom)
was given. Thin-walled stretch polytetrafluoroethylene
grafts (Gore-Tex, WL Gore & Associates, Flagstaff, Ariz)
with a wall thickness of 0.5 mm and an internal diameter of
either 6 mm or 4 mm to 7 mm tapered, from arterial to
venous site, were positioned in a subcutaneous loop with
the use of a 6-mm tunneler device (Kelly-Wick, Bard Impra
Inc, Tempe, Ariz) in the forearm between the brachial
artery and a suitable elbow vein. Both brachial artery and
antecubital vein diameter were measured with coronary
probes, which were calibrated with 0.5-mm increments.
Arterial and venous anastomoses were created with running
7-0 polypropylene monofilament sutures (Prolene, Ethi-
con, Johnson & Johnson, Amersfoort, The Netherlands).
Coumarin (Sintrom, acenocoumarol, Novartis Pharma
GmbH, Nu¨rnberg, Germany) was given after surgery to all
patients in a dosage that was sufficient for an adequate
anticoagulation (international normalized ratio, 2.5).
Follow-up. Duplex ultrasound scan examination was
performed at 1 month, 6 months, and 12 months after
surgery. All patients were examined in the supine position
with B-mode ultrasound scan imaging and Doppler spec-
trum analysis of the brachial artery, the arterial anastomosis,
the graft, the venous anastomosis, and the efferent vein up
to the subclavian vein. Peak systolic velocity (PSV; m/s),
end diastolic velocity (m/s), and diameter were measured
at defined sites and saved as video prints. Significant steno-
ses with lumen diameter reductions of 50% or more were
diagnosed according to previously reported criteria.33 Also,
volume flow (mL/min) was measured in the brachial artery
and the prosthesis.
Angiography of the arteriovenous grafts was performed
3 months after surgery. The graft, venous anastomosis, and
outflow tract were visualized according to a technique as
reported by Staple.34 The percentage of diameter reduction
was calculated as the quotient of the diameter in the steno-
sis and the diameter of the adjacent normal vessel. Only
stenoses with a lumen diameter reduction of 50% or more
were analysed.
Clinical follow-up was performed during the follow-up
period of 12 months, and early (30 days) and late com-
plications and the intervention of choice, radiologic or
surgical, were registered. Complications were treated ac-
cording to standard clinical practice of the hospital where
the patient was being treated.
Endpoints. Endpoints were reached in case of irre-
versible graft failure, death, successful renal transplantation,
or transfer to continuous ambulatory peritoneal dialysis
treatment.
Statistical analysis. For data management and statis-
tical analysis, the SPSS 10.0 package for Windows (SPSS,
Inc, Chicago, Ill) was used. Before inclusion, a sample size
estimation with a power of 0.95 and a double-sided signif-
icance of 0.05 was performed to determine the smallest
number of patients needed per group to acquire an im-
provement in 1-year primary patency rate of 25%, which
corresponded to about 55 patients per study group. Patient
characteristics and clinical variables were analyzed with the
independent samples t test and the 2 test and the Fisher
exact test where obligatory. Patency rates ( standard
error) were obtained through Kaplan-Meier life-table anal-
ysis and compared with the log-rank test. Primary patency
rate was defined as the percentage of grafts that functioned
well without any intervention after implantation. Primary
assisted patency was defined as the percentage of failing but
still patent grafts undergoing elective intervention, and
secondary patency was defined as the proportion of patent
grafts still in use for hemodialysis after successful interven-
tion for graft thrombosis.35 Patients with a patent graft who
died, received a transplant kidney, or withdrew from hemo-
dialysis therapy alive were censored.
The incidence rate was defined as the number of com-
plications or interventions per py, the cumulative follow-up
time of all patients,36 and analyzed with Poisson regression
analysis. Risk factors, endpoints, duplex ultrasound scan,
Doppler spectral analysis parameters, and angiographic
findings in both groups were compared with the indepen-
dent samples t test and the 2 test and correlated with
patency with simple linear regression. Data are presented as
the group mean  standard deviation. Differences were
considered statistically significant when the P value was less
than .05.
RESULTS
Patient characteristics and trial endpoints. In-
formed consent was obtained from 109 patients, of whom
52 were randomized for 4-mm to 7-mm tapered prosthetic
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brachial-antecubital forearm loop access. Equal distribu-
tions were seen regarding the preoperative patient charac-
teristics that are displayed in Table I. Also, local risk factors
were alike in both groups (Table I).
Before surgery, vein (4.4  0.8 mm versus 4.7  1.1
mm, 4-mm to 7-mm versus 6-mm, respectively; P  .05)
and artery (4.0  0.9 mm versus 3.9  0.6 mm, 4-mm to
7-mm versus 6-mm, respectively; P  .05) diameters were
not different in either group. Direct postoperative (30
days) complications were seen in 29 patients with the
tapered graft and in 32 patients with the 6-mm prosthesis,
the most important being thrombosis of the graft (9 versus
8, respectively; P  .05) and local edema (8 versus 8,
respectively; P .05) subsiding as a matter of course. Early
occlusion was successfully treated with surgical thrombec-
tomy in all cases. Total follow-up time was 33.9 py for the
tapered group and 34.0 py for the 6-mm graft group. In
Table II, the endpoints at 12 months of follow-up are
presented. Seventy-one percent of the patients in the 4-mm
to 7-mm tapered group and 67% in the 6-mm group
reached the endpoint with a patent graft. Twenty patients
died of complications of their kidney failure with a patent
graft, and four patients underwent successful kidney trans-
plantation.
Patency rates, complications, and interventions.
Regarding patency rates ( standard error), comparable
results were obtained between the two groups. For the
4-mm to 7-mm tapered prosthesis group, primary patency
rates of 70% ( 6.8%) at 6 months and 46% ( 7.9%) at 1
year were seen. The 6-month and 1-year primary patency
rates in the 6-mm graft group were 72% and 43% ( 6.7%
and 7.8%), respectively (P  .860; Fig 1). The primary
assisted patency rates were 85% ( 5.4%) at 6 months and
62% ( 7.9%) at 1 year in the 4-mm to 7-mm tapered graft
group and 74% and 58% ( 6.5% and 7.6%) in the 6-mm
prosthesis group (P  .492). The secondary patency rate
was also similar (Fig 2): 96% ( 3.1%) at 6 months and 87%
( 5.5%) at 1 year in the tapered group and 94% and 91%
( 3.6% and 4.4%) in the 6-mm polytetrafluoroethylene
prosthesis group (P  .727). At 1.5 and 2 years, the
secondary patency rates were still equal: 85% and 69%
( 6.7% and 10.4%) in the tapered group and 77% and 61%
( 7.6% and 10.5%) in the 6-mm group (P  .468).
A total of 25 (0.74/py) and 30 (0.88/py; P  .05)
interventions were needed in the tapered and the 6-mm
grafts, respectively. Thrombosis and stenosis were the rea-
sons for intervention on 21 (0.62/py) and 23 (0.68/py;
P .05) occasions. A thrombectomy was performed on 13
(0.38/py) and eight (0.24/py; P  .05) occasions, and
percutaneous transluminal angioplasty was done in eight
(0.24/py) and 15 (0.44/py; P .05) cases in the 4-mm to
7-mm and 6-mm grafts. Occasionally, revision (0.03/py in
the tapered group and 0.06/py in the 6-mm group; P 
.05) and fibrinolysis (0.03 in the 6-mm group; P  .05)
were added to treat a graft with stenotic lesions. Infection
was seen significantly more often in the tapered prosthesis
group (four times [0.12/py] versus once [0.03/py]; P 
.05). In four of these patients, graft explantation was nec-
essary. Ischemia was observed three times (twice in the
6-mm graft group) and was treated with flow reduction
through banding of the graft. Only one patient in the
6-mm group underwent treatment for high-output cardiac
failure with graft explantation.
Duplex scan and angiographic results. In Table III,
hemodynamic parameters measured with duplex scan at 12
months are presented. No differences were seen in PSVs in
any part of the graft at any time point in the follow-up.
After 1 and 6 months, mean graft flow was 1416  539
mL/min and 1470  638 mL/min in the 4-mm to 7-mm
tapered grafts and 1415  525 mL/min and 1494  762
mL/min in the 6-mm grafts, respectively (P  .05). No
correlation was found between the volume flow, PSVs, and
the primary or secondary patency rates. The percentage of
stenoses detected with duplex scanning was 15% and 17% at
1 month (P  .05), 23% and 19% at 6 months (P  .05),
and 27% and 20% at 1 year (P  .05) in the tapered graft
and the 6-mm graft groups, respectively.
Fistulography at 3 months in 43 patients revealed six
(33.3%) and nine (36.0%) stenoses, defined as50% diam-
eter reduction, in the tapered (n  18) and 6-mm graft
groups (n  25; P  .05). No significant differences were
found in the distribution of the stenoses between both
groups.
Analysis of risk factors. No correlation was found
between the presence of risk factors listed in Table I and the
occurrence of graft failure. Also, preoperative medication
intake, such as statins, angiotensin converting enzyme in-
hibitors, acetylsalicylic acid, and erythropoietin, and preop-
erative vein and artery diameters were not related to graft
failure and patency.
DISCUSSION
Because of reports that showed reduced shear stress
induced intimal hyperplasia with different geometric con-
Table I. Preoperative patient characteristics
4 mm to
7 mm 6 mm P value
Age (y) 63.5  13.3 64.4  13.2 .713
Male gender 16 (30.8%) 24 (42.1%) .239
Previous accesses 25 (48.1%) 26 (46.4%) .831
Previous HD (mo) 6.1  19.1 6.4  12.7 .932
Previous CAPD (mo) 5.1  14.8 3.7  11.5 .615
Medical history
Smoking 14 (27.5%) 13 (23.6%) .570
Diabetes mellitus 21 (41.2%) 15 (22.3%) .104
Hypertension 27 (51.9%) 29 (50.9%) .913
Ischemic cardiac disease 16 (30.8%) 16 (28.1%) .757
Peripheral vascular disease 9 (17.3%) 11 (19.3%) .789
Cerebrovascular disease 9 (17.3%) 5 (8.8%) .183
Local risk factors
Edema 1 (1.9%) 0 .292
Skin atrophy 7 (13.5%) 6 (10.5%) .637
BMI  30 kg m–2 6 (11.5%) 9 (15.8%) .520
HD, Hemodialysis; CAPD, continuous ambulatory peritoneal dialysis; BMI,
body mass index.
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figurations of the polytetrafluoroethylene arteriovenous fis-
tula,22,23,25,27 this prospective randomized clinical trial was
performed and showed no differences in either thrombotic
occlusion or patency rates between 4-mm to 7-mm tapered
prosthetic brachial-antecubital forearm loop access and
6-mm prosthetic brachial-antecubital forearm loop access.
Tapering of the polytetrafluoroethylene graft has shown
opposing results in previous studies. For example, Fillinger
et al27 have shown that graft geometry (4-mm to 7-mm)
might have a significant impact on hemodynamic factors
and venous intimal hyperplasia in arteriovenous loop grafts
in mongrel dogs. The same results were obtained by Keyn-
ton and coworkers19,32 in a mongrel dog carotid artery
bypass model. Moreover, a 6-mm to 8-mm brachioaxillary
polytetrafluoroethylene graft was used for hemodialysis in
157 patients with acceptable patency rates. In this nonran-
domized study, a primary patency rate of 73% and a sec-
ondary patency rate of 91% at 1 year were reported.25 Some
studies, on the other hand, have shown contradictory re-
sults in that the risk for thrombosis was even higher in
tapered grafts of patients with diabetes29 and patency rates
were equal or inferior to those reported with 6-mm
grafts.28,29 The same holds for interposition vein cuffs; in
vitro results are promising,22,23,28,29,37 but implementa-
tion in a human setting is often disappointing.24,26
Fig 1. Primary patency rates. Patency rate is shown in percent-
ages, and survival time in days. Number of patients is presented in
graph. P values are calculated with log-rank test.
Fig 2. Secondary patency rates. Patency rate is shown in percent-
ages, and survival time in days. Number of patients is presented in
graph. P values are calculated with log rank test.
Table II. Study endpoints
4 mm to 7 mm Time 6 mm Time P value
Patent graft 37 (71.2%) 38 (66.7%) .614
Graft failure 2 (3.8%) 263  146 3 (5.3%) 320  51 .724
Kidney transplant 1 (1.9%) 310 3 (5.3%) 242  189 .354
Deceased 10 (19.2%) 169  146 10 (17.5%) 142  136 .820
Other 2 (3.8%) 162  209 3 (5.3%) 129  139 .724
Table III. Duplex scan findings at 12 months
4 mm to
7 mm 6 mm P value
Brachial artery flow
(mL/min)
1350  773 1185  501 .458
Graft flow (mL/min) 1595  659 1265  534 .189
Brachial artery PSV (m/s) 1.5  0.7 1.5  0.6 .662
Arterial anastomosis PSV
(m/s)
2.8  1.7 2.6  1.1 .826
Venous anastomosis PSV
(m/s)
3.0  1.0 2.0  1.5 .511
Efferent vein PSV (m/s) 1.5  1.2 1.7  1.3 .667
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The aforementioned studies showed that hemody-
namic parameters, especially shear stress, altered as a result
of a change in geometric configuration.19,21,23,27,30,32,37
Interestingly, we were not able to confirm these findings
with duplex ultrasonographic scanning in that PSVs and
graft flows were alike in 4-mm to 7-mm and 6-mm pros-
thetic brachial-antecubital forearm loop access. Further-
more, unpublished results in our laboratory showed that a
venous cuff at the venous anastomosis did not change wall
shear rate, calculated with Poiseuille’s formula with a para-
bolic flow profile, near the venous anastomosis (1329 [no
cuff] and 1137 s1) in goats. This would imply that in the
human setting there is no evident effect of changes in
vortices at the vessel wall, thus still inducing intimal hyper-
plasia.
Stenoses were seen as many times in tapered grafts as in
6-mm prostheses, although more thrombotic occlusions in
4-mm to 7-mm tapered grafts in patients with diabetes have
been reported before.29 Also, Sabanayagam28 has shown
inferior patency rates of 4-mm to 7-mm tapered prostheses
compared with 6-mm grafts. In our study, an equal distri-
bution of patients with diabetes was seen, and diabetes per
se was not related to graft failure. Inadequate compression
of cannulation sites after dialysis may also influence throm-
bosis and stenosis development. However, it remains diffi-
cult to exactly define this problem in dialysis access. Be-
sides, we contemplate that it might occur in the same
frequency in both types of grafts, although no evidence is
reported here. Furthermore, the use of medication (statins,
angiotensin converting enyzme inhibitors, acetylsalicylic
acid, and erythropoietin) was not related to a better out-
come.
Different reports have shown beneficial effects of graft
tapering in case of high output cardiac failure or peripheral
steal syndromes by reducing graft flow.28,38,39 In this
study, only two cases of ischemic complications were seen
in the 6-mm grafts and only one in the tapered prostheses.
No relation to high flow could be established in these
patients. Diabetes and underlying atherosclerotic disease
have been shown to be the main causes of peripheral steal
syndromes.25,40 Indeed, the patients with ischemic symp-
toms in this study all had diabetes. Because only a few
patients had a steal syndrome, we cannot postulate that
4-mm to 7-mm tapered grafts reduce ischemic symptoms
by reducing graft flow.
This study population showed significantly more infec-
tions in the 4-mm to 7-mm tapered group when compared
with the 6-mm graft group (four versus one). In only one of
the three infections observed in the tapered grafts, periop-
erative infection seemed to be the cause because infection
occurred within 14 days after surgery. In the other cases,
the mean ( standard deviation) time until onset of infec-
tion was 144  110 days, suggesting that the infections
were from repetitive puncture.
Because the choice in geometry does not seem to
influence hemodialysis vascular access function, as shown in
this study and others,24,26,28,29 it should be stressed that
monitoring vascular access might be of importance. Weekly
physical examination and regular hemodynamic monitor-
ing is important in detecting stenoses, and when combined
with correction, this will improve patency rates and de-
crease the incidence rate of thrombosis. The Kidney Dis-
ease Outcome Quality Initiative guidelines recommend
this organized monitoring approach.1 Moreover, more re-
search should be commenced in which the pathophysio-
logic mechanism of intimal hyperplasia is attacked. For
example, different cytokines have been linked to intimal
hyperplasia10,16 that are possible aims for interventions.
Also, cell cycle regulating proteins, being essential factors in
intimal hyperplasia, might be accessible for therapeutic
intervention.41,42
In summary, tapering of prosthetic brachial-antecubital
forearm loop accesses does not alter hemodynamic param-
eters at the venous anastomosis significantly. Moreover, the
incidence rates of stenoses and thrombotic occlusions are
not reduced. Also, it does not result in improved patency
rates, and therefore, we believe that for hemodialysis vas-
cular access the 4-mm to 7-mm polytetrafluoroethylene
graft has no strong indication for routine use.
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